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The genetic basis of melanoma susceptibility among Greek patients is uncharacterized. From 107 consecutive
cutaneous melanoma patients, we analyzed the CDKN2A and CDK4 loci among 18 early-onset (p40 years) and
two multiplex melanoma cases. Overall, we found three CDKN2A mutations (3/20; 15%), including one novel
nonsense mutation (Trp110Stop) and two Arg24Pro missense alterations. There were no mutations in ARF or
CDK4. CDKN2A mutations are not uncommon among Greek melanoma patients considering that none of the
mutation carriers reported a family history of melanoma.
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Germline mutations in the CDKN2A gene have now been
identified in many hereditary melanoma kindreds worldwide
(Buday and Downward, 1993; Kefford et al., 1999; Bishop
et al., 2002). Overall, the rate of mutation among kindreds
with three or more affecteds is approximately 40% (Kefford
et al., 1999). Prevalence estimates for CDKN2A mutations
have been predominantly generated from northern European-
derived populations. In this regard, little is known about the
genetic landscape of high-risk melanoma patients from
Greece. To date, there are no published molecular analyses
of melanoma patients from Greece. We thus set out to
characterize the CDKN2A status of melanoma patients from a
large hospital-based melanoma unit in Athens, Greece.
This study was approved by an Institutional Review Board
at the A. Sygros Hospital, Athens, Greece. Between 2003 and
2005, 107 consecutive melanoma patients were referred to
the A. Syngrous hospital for treatment or surveillance and
were enrolled for the study. We identified a subgroup of
patients with a history suggestive of a cancer syndrome
including 26 individuals with early-onset melanoma (iep40
years of age), three individuals with multiple primary
cutaneous melanomas, and two patients with a family history
of melanoma. From these 31 patients, a total of 20 individuals
(18 with early-onset melanoma and two with multiple
primary melanomas) agreed to donate blood for analysis.
All DNA was extracted using the DNA Mini-Blood Extraction
Kit (Qiagen, Valencia, CA) according to the manufacturer’s
protocol.
We performed direct sequencing of CDKN2A exons 1a
and 2 using primers and conditions that have been previously
published (Hogg et al., 2001). We also screened for CDKN2A
exon 1b mutations, the CDKN2A IVS2-105 mutation, and the
CDK4 Arg24Cys and Arg24His mutations by single-strand
conformation polymorphism conformation (SSCP) analysis as
previously described (Tsao et al., 1998). CDKN2A exon 1b
was screened using two overlapping sets of primers: p14ARF-
96F (50-GCTCAGGGAAGGCGGGTGC-30); p14ARF-320R
(50-AACCCTCACTCGCGGCGG-30); p14ARF-253F (50-ACAT
GGTGCGCAGGTTCTTGGT-30); p14ARF-473R (50-CCGGA
CTTTTCGAGGGCCTTT-30), while the IVS2-105 A/G muta-
tion was screened using p16-IV2 7453F (50-ACCAGGGAGGT
GTGGGAGAG-30) and p16-IV2 7647R (50-TGGTTCTTTCAA
TCGGGGATG-30).
The clinical features and genotype status of the patients in
this study are listed in Table 1. From 18 early-onset
melanoma patients, there was a single Trp110Stop alteration.
This appears to be a novel germline mutation although it has
been reported as a somatic mutation (Ruas and Peters, 1998).
Both multiple melanoma cases had the previously reported
Arg24Pro mutation (Ruas and Peters, 1998). There were no
alterations detected in ARF or CDK4. None of the mutation
carriers reported a family history of melanoma.
Based on our results, the rates of CDKN2A mutations were
5.6% (1/18) and 100% (2/2) among early-onset and multiple
primary melanoma patients, respectively. Previous studies
have found a similar rate of CDKN2A mutations among early-
onset patients in the United States (Tsao et al., 2000).
Although the number of patients with multiple primary
lesions is extremely low, the detection of germline mutations
in both individuals with multiple primary melanomas is
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surprising. Past investigations have described CDKN2A
mutation rates of 5–15% among patients with multiple
primary melanomas (MacKie et al., 1998; Monzon et al.,
1998; Hashemi et al., 2000). Our CDKN2A mutation carriers
also lacked a family history of melanoma. The absence of
familial predisposition in these index cases may reflect less
widespread cutaneous surveillance in the population and
thus, a bias toward underdetection and underreporting.
Alternatively, there may be more pervasive protective
modifier genes that reduce the penetrance of the mutant
alleles. It is indeed possible that in regions of low ambient
melanoma incidence, the hereditary cancer phenotype (ie
early age of onset or multiple primary melanomas), even
without a family history, predicts a higher rate of heritable
defects compared to areas of high melanoma incidence,
where phenocopies may dilute the prevalence of mutation
carriers. Clearly, additional cases are needed to derive a more
accurate estimate.
In summary, we report the largest genetic analysis to date
of germline CDKN2A mutations among melanoma patients
from Greece. The observed 15% rate among early-onset and
multiplex melanoma cases indicates that heritable suscept-
ibility to cutaneous melanoma is not uncommon in the native
Hellenic population.
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